Performance and Robustness of the Monte Carlo Importance Sampling Algorithm Using Parallelized S-ADAPT for Basic and Complex Mechanistic Models
暂无分享,去创建一个
[1] W. Jusko,et al. Note: Caution in Use of Empirical Equations for Pharmacodynamic Indirect Response Models , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[2] Jelliffe Rw. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. , 1991 .
[3] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic data , 1980, Journal of Pharmacokinetics and Biopharmaceutics.
[4] A. Schumitzky. Nonparametric EM Algorithms for estimating prior distributions , 1991 .
[5] Mats O. Karlsson,et al. Performance in population models for count data, part I: maximum likelihood approximations , 2009, Journal of Pharmacokinetics and Pharmacodynamics.
[6] É. Moulines,et al. Convergence of a stochastic approximation version of the EM algorithm , 1999 .
[7] A Schumitzky,et al. A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.
[8] Lewis B. Sheiner,et al. Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic data , 1981, Journal of Pharmacokinetics and Biopharmaceutics.
[9] S. Ait-Oudhia,et al. Simultaneous Pharmacokinetics/Pharmacodynamics Modeling of Recombinant Human Erythropoietin upon Multiple Intravenous Dosing in Rats , 2010, Journal of Pharmacology and Experimental Therapeutics.
[10] D. DuBois,et al. Mechanism-Based Modeling of Nutritional and Leptin Influences on Growth in Normal and Type 2 Diabetic Rats , 2009, Journal of Pharmacology and Experimental Therapeutics.
[11] D J Roe. Comparison of population pharmacokinetic modeling methods using simulated data: results from the Population Modeling Workgroup. , 1997, Statistics in medicine.
[12] A. Joshi,et al. Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis , 2005, Pharmaceutical Research.
[13] Ss Beal,et al. NONMEM User’s Guides. (1989–2009) , 2009 .
[14] L. Petzold. Automatic Selection of Methods for Solving Stiff and Nonstiff Systems of Ordinary Differential Equations , 1983 .
[15] D. Rubin,et al. Maximum likelihood from incomplete data via the EM - algorithm plus discussions on the paper , 1977 .
[16] Robert J. Bauer,et al. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.
[17] A. Tolcher,et al. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.
[18] T. Wajima,et al. A Comprehensive Model for the Humoral Coagulation Network in Humans , 2009, Clinical pharmacology and therapeutics.
[19] Mats O. Karlsson,et al. Mechanistic Models for Myelosuppression , 2003, Investigational New Drugs.
[20] Richard R. Almon,et al. Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis I: Mechanistic Disease Progression Model for the Time Course of Collagen-Induced Arthritis in Lewis Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.
[21] Alan Schumitzky,et al. Model-Based, Goal-Oriented, Individualised Drug Therapy , 1998, Clinical pharmacokinetics.
[22] Stephen G Walker,et al. AN EM ALGORITHM FOR NONLINEAR RANDOM EFFECTS MODELS , 1996 .
[23] N. Laird. Nonparametric Maximum Likelihood Estimation of a Mixing Distribution , 1978 .
[24] W. Jusko,et al. Mechanistic population pharmacokinetics of total and unbound paclitaxel for a new nanodroplet formulation versus Taxol in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.
[25] Richard R Almon,et al. Modeling Corticosteroid Effects in a Rat Model of Rheumatoid Arthritis II: Mechanistic Pharmacodynamic Model for Dexamethasone Effects in Lewis Rats with Collagen-Induced Arthritis , 2008, Journal of Pharmacology and Experimental Therapeutics.
[26] Robert Leary,et al. Parametric and Nonparametric Population Methods , 2006, Clinical pharmacokinetics.
[27] Wojciech Krzyzanski,et al. Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations , 2009, Clinical pharmacokinetics.
[28] R W Jelliffe. The USC*PACK PC programs for population pharmacokinetic modeling, modeling of large kinetic/dynamic systems, and adaptive control of drug dosage regimens. , 1991, Proceedings. Symposium on Computer Applications in Medical Care.
[29] Neang S. Ly,et al. Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.
[30] Mats O. Karlsson,et al. Nonlinearity detection: Advantages of nonlinear mixed-effects modeling , 2000, AAPS PharmSci.
[31] C. Takimoto,et al. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients , 2011, Cancer Chemotherapy and Pharmacology.
[32] New York Dover,et al. ON THE CONVERGENCE PROPERTIES OF THE EM ALGORITHM , 1983 .
[33] E. Kuhn,et al. Coupling a stochastic approximation version of EM with an MCMC procedure , 2004 .
[34] H. Fung,et al. Pharmacokinetics of 1,4-Butanediol in Rats: Bioactivation to γ-Hydroxybutyric Acid, Interaction with Ethanol, and Oral Bioavailability , 2008, The AAPS Journal.
[35] Eric Moulines. Convergence of a stochastic approximation version of the EMalgorithmMarc Lavielle , 1997 .
[36] Donald E Mager,et al. Integrated Cellular Bone Homeostasis Model for Denosumab Pharmacodynamics in Multiple Myeloma Patients , 2008, Journal of Pharmacology and Experimental Therapeutics.
[37] J F Boisvieux,et al. Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model. , 1984, Drug metabolism reviews.
[38] Xiaoning Wang,et al. Nonlinear random effects mixture models: Maximum likelihood estimation via the EM algorithm , 2007, Comput. Stat. Data Anal..
[39] Wojciech Krzyzanski,et al. Indirect Pharmacodynamic Models for Responses with Multicompartmental Distribution or Polyexponential Disposition , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[40] DE Mager,et al. Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.
[41] D. Lalloo,et al. A model for venom-induced consumptive coagulopathy in snake bite. , 2008, Toxicon : official journal of the International Society on Toxinology.
[42] J. Verweij,et al. Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements , 2008, Clinical pharmacology and therapeutics.
[43] Stuart L. Beal,et al. Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.
[44] Stephen B Duffull,et al. ANALYSIS OF POPULATION PHARMACOKINETIC DATA USING NONMEM AND WinBUGS , 2004, Journal of biopharmaceutical statistics.
[45] Siv Jönsson,et al. Estimating Bias in Population Parameters for Some Models for Repeated Measures Ordinal Data Using NONMEM and NLMIXED , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[46] David Z. D'Argenio,et al. Physiologically-Based Pharmacokinetics and Molecular Pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and Its Active Metabolite in Tumor-Bearing Mice , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[47] Robert J. Bauer,et al. Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/Pharmacodynamic Data , 2004 .
[48] David Z. D'Argenio,et al. Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis , 2004, Springer US.
[49] Alan E. Gelfand,et al. Bayesian statistics without tears: A sampling-resampling perspective , 1992 .
[50] Neang S. Ly,et al. Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model , 2010, Antimicrobial Agents and Chemotherapy.